Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katzman, M
Right arrow Articles by Chan, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Katzman, M
Right arrow Articles by Chan, C.

Chest, Vol 101, 79-81, Copyright © 1992 by American College of Chest Physicians

ARTICLES

High incidence of bronchospasm with regular administration of aerosolized pentamidine

M Katzman, W Meade, K Iglar, A Rachlis, P Berger and CK Chan
Department of Medicine, Wellesley Hospital, Sunnybrook Medical Center, Canada.

A systematic evaluation of changes in pulmonary status by objective spirometric assessment and subjective rating using visual analog scale was performed in a cohort of 134 patients receiving aerosolized pentamidine (AP) for the prevention of Pneumocystis carinii pneumonia. Significant bronchospasm defined as greater than or equal to 15 percent reduction in the forced expiratory volume in 1 s was noted in 26 of 100 (26 percent) of patients receiving AP alone. Despite the use of salbutamol (albuterol) as concurrent aerosolized treatment in 34 subjects, bronchospasm developed in 9 of 34 (26 percent) of the patients. The subjective respiratory status rating scale was found to be unreliable in correctly predicting the development of bronchospasm. We conclude that a high incidence of bronchospasm is present in patients receiving regular AP administration using an ultrasonic nebulizer as studied, and concurrent administration of salbutamol is not fully protective of this acute adverse pulmonary reaction.


This article has been cited by other articles:


Home page
 ChestHome page
J. Obaji, L. R. Lee-Pack, C. Gutierrez, and C. K.N. Chan
The Pulmonary Effects of Long-term Exposure to Aerosol Pentamidine: A 5-Year Surveillance Study in HIV-Infected Patients
Chest, June 1, 2003; 123(6): 1983 - 1987.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Chest Physicians.